Intelligence for Ophthalmology Specialists

Ophthalmology clinical trials
recruiting in the United States and Brazil

Up-to-date overview of clinical trials in age-related macular degeneration (AMD), geographic atrophy, diabetic retinopathy, diabetic macular edema, glaucoma, uveitis, Stargardt disease, retinitis pigmentosa, Leber congenital amaurosis, Usher syndrome, dry eye disease, keratoconus, thyroid eye disease and other ophthalmic conditions recruiting patients in the US and Brazil — automatically compiled from ClinicalTrials.gov. Refer eligible patients to participating research centers.

126

Active trials

855

US sites

Indications covered

BR trials

Loading map…

126 studies found

N/DPrimary Open Angle GlaucomaMyopiaUS 1 site in the US

Diagnostic Innovations in Glaucoma Study

University of California, San Diego

📍 La Jolla👥 3000 participants📅 Completion: 2030-07

View details →Refer patient →ClinicalTrials.gov ↗

N/DAge Related Macular DegenerationDiabetic RetinopathyVon Hippel Lindau SyndromeUS 1 site in the US

National Eye Institute Biorepository for Retinal Diseases

National Eye Institute (NEI)

📍 Bethesda👥 650 participants

View details →Refer patient →ClinicalTrials.gov ↗

N/DStargardt DiseaseRetinite PigmentosaDegeneracao Macular Relacionada a IdadeUS 1 site in the US

High Resolution Retinal Imaging

University of Pennsylvania

📍 Philadelphia👥 600 participants📅 Completion: 2027-12

View details →Refer patient →ClinicalTrials.gov ↗

N/DGlaucomaUS 1 site in the US

Eye Pressure Lowering Surgery

Oregon Health and Science University

📍 Portland👥 46 participants📅 Completion: 2026-05

View details →Refer patient →ClinicalTrials.gov ↗

N/DGlaucomaNormal ControlUS 1 site in the US

Functional and Structural Imaging for Glaucoma

Oregon Health and Science University

📍 Portland👥 160 participants📅 Completion: 2026-05

View details →Refer patient →ClinicalTrials.gov ↗

N/DNeovascular Age Related Macular DegenerationOlhos Saudaveis ControleUS 1 site in the US

OCT Angiography in Wet AMD

Oregon Health and Science University

📍 Portland👥 160 participants📅 Completion: 2026-12

View details →Refer patient →ClinicalTrials.gov ↗

N/DAcromatopsiaSindrome de Bardet BiedlSindrome de Bassen KornzweigUS 1 site in the US

Inherited Retinal Degenerative Disease Registry

Foundation Fighting Blindness

📍 Columbia👥 20000 participants📅 Completion: 2037-06

View details →Refer patient →ClinicalTrials.gov ↗

N/DRetinitis PigmentosaDegeneracao RetinianaDoenca de StargardtUS 1 site in the US

Rod and Cone Mediated Function in Retinal Disease

National Eye Institute (NEI)

📍 Bethesda👥 500 participants📅 Completion: 2029-12

View details →Refer patient →ClinicalTrials.gov ↗

N/DMultiple SclerosisDry EyeDiabetic RetinopathyUS 1 site in the US

Clinical Applications of Advanced Ophthalmic Imaging

University of Miami

📍 Miami👥 5000 participants📅 Completion: 2029-12

View details →Refer patient →ClinicalTrials.gov ↗

Fase 1Degeneracao Macular Relacionada a Idade SecaUS 12 sites in the US

A Study of the Safety and Tolerability of ASP7317 in Senior Adults Who Are Losing Their Clear, Sharp Central Vision Due to Geographic Atrophy Secondary to Dry Age-related Macular Degeneration

Astellas Institute for Regenerative Medicine

📍 Ann Arbor, Atlanta, Boston, Dallas, Los Angeles, Oak Forest, Palo Alto, Pensacola👥 42 participants📅 Completion: 2026-06

View details →Refer patient →ClinicalTrials.gov ↗

N/DRetinopatia DiabeticaUS 1 site in the US

Liver X Receptor (LXR) as a Novel Therapeutic Target in Diabetic Retinopathy (DR)

University of Alabama at Birmingham

📍 Birmingham👥 104 participants📅 Completion: 2026-12

View details →Refer patient →ClinicalTrials.gov ↗

N/DDiabetic RetinopathyDiabetes ComplicationsUS 1 site in the US

Human iPSC for Repair of Vasodegenerative Vessels in Diabetic Retinopathy

University of Alabama at Birmingham

📍 Birmingham👥 20 participants📅 Completion: 2027-12

View details →Refer patient →ClinicalTrials.gov ↗

N/DGlaucoma Primario Angulo AbertoSujeitos Saudaveis Sem Doenca OcularUS 1 site in the US

Caffeine Consumption in Glaucoma Patients and Healthy Subjects

Wills Eye

📍 Philadelphia👥 80 participants📅 Completion: 2026-12

View details →Refer patient →ClinicalTrials.gov ↗

N/DMacular HolesEpiretinal MembraneDiabetic RetinopathyUS 1 site in the US

Intraoperative OCT Guidance of Intraocular Surgery II

Duke University

📍 Durham👥 262 participants📅 Completion: 2027-05

View details →Refer patient →ClinicalTrials.gov ↗

N/DAge Related Macular DegenerationRetinopatia DiabeticaGlaucomaUS 1 site in the US

Village-Integrated Eye Worker Trial II

University of California, San Francisco

📍 San Francisco👥 60200 participants📅 Completion: 2029-08

View details →Refer patient →ClinicalTrials.gov ↗

Fase 3Glaucoma Angulo AbertoUS 2 sites in the US

Pilocarpine Use After Kahook Goniotomy

Montefiore Medical Center

📍 The Bronx👥 142 participants📅 Completion: 2028-12

View details →Refer patient →ClinicalTrials.gov ↗

Fase 1RetinopatiaOclusao Venosa RetinianaRetinopatia DiabeticaUS 1 site in the US

Feasibility and Safety of MB-102 in Ocular Angiography as Compared to Fluorescein Sodium

MediBeacon

📍 Ann Arbor👥 10 participants📅 Completion: 2026-12

View details →Refer patient →ClinicalTrials.gov ↗

Fase 1Cystoid Macular EdemaUS 1 site in the US

Therapeutic Contact Lens Drug Delivery System (TCL-DDS) in Patients With Recurrent Cystoid Macular Edema

Massachusetts Eye and Ear Infirmary

📍 Boston👥 6 participants📅 Completion: 2027-12

View details →Refer patient →ClinicalTrials.gov ↗

Fase 1Degeneracao Macular Relacionada a Idade SecaAtrofia GeograficaUS 1 site in the US

Autologous Transplantation of Induced Pluripotent Stem Cell-Derived Retinal Pigment Epithelium for Geographic Atrophy Associated With Age-Related Macular Degeneration

National Eye Institute (NEI)

📍 Bethesda👥 20 participants📅 Completion: 2029-05

View details →Refer patient →ClinicalTrials.gov ↗

N/DGlaucomaDoenca da Superficie OcularUS 1 site in the US

Treatment of Ocular Discomfort in Glaucoma Patients Using Multiple Topical Medications

University of California, Los Angeles

📍 Fountain Valley👥 75 participants📅 Completion: 2026-12

View details →Refer patient →ClinicalTrials.gov ↗

Fase 1Glaucoma de Angulo AbertoHipertensao OcularUS 29 sites in the US

AGN-193408 SR in the Treatment of Open-angle Glaucoma or Ocular Hypertension

AbbVie

📍 Austin, Boston, Brandon, Chesterfield, Chicago, Columbus, Crystal River, Danbury👥 96 participants📅 Completion: 2029-02

View details →Refer patient →ClinicalTrials.gov ↗

Fase 2Wet Age Related Macular DegenerationUS 1 site in the US

MMP-9 Inhibition for Recalcitrant Wet AMD

University of Iowa

📍 Iowa City👥 50 participants📅 Completion: 2027-03

View details →Refer patient →ClinicalTrials.gov ↗

N/DDiabetic RetinopathyRetinal Vein OcclusionHipertensao EssencialUS 1 site in the US

Optical Coherence Tomography Angiography in Subjects With Retinal Vascular Disease

Johns Hopkins University

📍 Baltimore👥 1050 participants📅 Completion: 2026-09

View details →Refer patient →ClinicalTrials.gov ↗

Fase 2Diabetes Mellitus Tipo 2Retinopatia DiabeticaDisturbios do SonoUS 1 site in the US

Sleep, Diabetic Retinopathy and Melatonin

University of Illinois at Chicago

📍 Chicago👥 42 participants📅 Completion: 2026-06

View details →Refer patient →ClinicalTrials.gov ↗

Fase 1Dry Age Related Macular DegenerationUS 3 sites in the US

Safety and Tolerability of RPE Stem Cell-derived RPE(RPESC-RPE) Transplantation in Patients With Dry Age-related Macular Degeneration (AMD)

Luxa Biotechnology, LLC

📍 Ann Arbor, Beverly Hills, Palo Alto👥 18 participants📅 Completion: 2026-12

View details →Refer patient →ClinicalTrials.gov ↗

Fase 3Retinopatia DiabeticaUS 66 sites in the US

Fenofibrate for Prevention of DR Worsening

Jaeb Center for Health Research

📍 Augusta, Austin, Ayer, Baltimore, Beaumont, Bellaire, Boston, Chapel Hill👥 560 participants📅 Completion: 2029-12

View details →Refer patient →ClinicalTrials.gov ↗

Fase 3Hipertensao OcularGlaucoma Primario de Angulo Aberto LeveGlaucoma Primario de Angulo Aberto ModeradoUS 27 sites in the US

Clarifying the Optimal Application of SLT Therapy Trial

University of Pittsburgh

📍 Ann Arbor, Baltimore, Boston, Chicago, Cleveland, Detroit, Fort Worth, Kingston👥 790 participants📅 Completion: 2027-08

View details →Refer patient →ClinicalTrials.gov ↗

N/DRetinopatia DiabeticaUS 3 sites in the US

Biomarker of Diabetic Retinopathy

Indiana University

📍 Carmel, Indianapolis👥 192 participants📅 Completion: 2026-06

View details →Refer patient →ClinicalTrials.gov ↗

Fase 1Neovascular Wet Age Related Macular DegenerationUS 19 sites in the US

4D-150 in Patients With Neovascular (Wet) Age-Related Macular Degeneration

4D Molecular Therapeutics

📍 Austin, Bethlehem, Boston, Carmel, Eugene, Gainesville, Hagerstown, Lakewood👥 215 participants📅 Completion: 2031-01

View details →Refer patient →ClinicalTrials.gov ↗

Fase 1GlaucomaNeuropatia Optica Isquemica Anterior Nao ArteríticaDrusas do Disco OpticoUS 1 site in the US

Topical Insulin for Glaucoma

Stanford University

📍 Palo Alto👥 52 participants📅 Completion: 2026-12

View details →Refer patient →ClinicalTrials.gov ↗

Fase 4GlaucomaUS 4 sites in the US

Retinal Blood Flow and Autoregulation

University of Maryland, Baltimore

📍 Baltimore, Silver Spring👥 90 participants📅 Completion: 2027-09

View details →Refer patient →ClinicalTrials.gov ↗

N/DGlaucoma Primario Angulo AbertoUS 1 site in the US

Adaptive Optics Retinal Imaging

Food and Drug Administration (FDA)

📍 Silver Spring👥 80 participants📅 Completion: 2026-09

View details →Refer patient →ClinicalTrials.gov ↗

N/DAge Related Macular DegenerationGeographic AtrophyUS 10 sites in the US

Multicenter Clinical Study of the SING-IMT in Patients with Late-stage AMD

VisionCare, Inc.

📍 Asheville, Birmingham, Cleveland, Eatontown, Houston, Lawrence, Loma Linda, Long Beach👥 125 participants📅 Completion: 2025-12

View details →Refer patient →ClinicalTrials.gov ↗

N/DMacular DegenerationCentral Visual ImpairmentUS 1 site in the US

Factors in Learning And Plasticity: Macular Degeneration

University of Alabama at Birmingham

📍 Birmingham👥 60 participants📅 Completion: 2026-11

View details →Refer patient →ClinicalTrials.gov ↗

N/DType 1 DiabetesType 2 DiabetesCystic Fibrosis Related DiabetesUS 1 site in the US

ACCESS 2: AI for pediatriC diabetiC Eye examS Study 2

Johns Hopkins University

📍 Baltimore👥 500 participants📅 Completion: 2026-06

View details →Refer patient →ClinicalTrials.gov ↗

N/DGlaucomaUS 1 site in the US

Comparison of Intraocular Pressure Measurement With the Novel TonoVera Device With Other Commonly Used Devices

State University of New York at Buffalo

📍 Buffalo👥 300 participants📅 Completion: 2025-12

View details →Refer patient →ClinicalTrials.gov ↗

N/DRetinopatia da PrematuridadeUS 1 site in the US

Imaging Retinal Vasculature in Infant Eyes

Duke University

📍 Durham👥 16 participants📅 Completion: 2027-08

View details →Refer patient →ClinicalTrials.gov ↗

N/DPrimary Open Angle GlaucomaUS 1 site in the US

Cataract Surgery in Conjunction With Ab-interno Canaloplasty Compared to Cataract Surgery Only in Patients With Mild to Moderate Primary Open-Angle Glaucoma

Nova Eye, Inc.

📍 Sugar Land👥 78 participants📅 Completion: 2027-07

View details →Refer patient →ClinicalTrials.gov ↗

N/DGlaucoma Angulo AbertoCatarataUS 1 site in the US

Results of Patients With Glaucoma Undergoing Minimally Invasive Glaucoma Surgery in Conjunction With Cataract Surgery

Vold Vision P.L.L.C

📍 Fayetteville👥 25 participants📅 Completion: 2025-05

View details →Refer patient →ClinicalTrials.gov ↗

Fase 2Geographic AtrophyUS 15 sites in the US

A Study to Optimize Subretinal Surgical Delivery and to Evaluate Safety and Activity of Opregen in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration (GAlette); Adaptive Optics (AO) Retinal Imaging Substudy in Association With Study GR44251

Genentech, Inc.

📍 Austin, Baltimore, Bellaire, Beverly Hills, Blue Ash, Durham, Lynchburg, Nashville👥 60 participants📅 Completion: 2031-03

View details →Refer patient →ClinicalTrials.gov ↗

N/DAge Related Macular DegenerationAllergiesAlpha Gal SyndromeUS 1 site in the US

Tissue Repository Providing Annotated Biospecimens for Approved Investigator-directed Biomedical Research Initiatives

Sanguine Biosciences

📍 Waltham👥 20000 participants📅 Completion: 2025-10

View details →Refer patient →ClinicalTrials.gov ↗

N/DGlaucoma Primario Angulo AbertoGlaucoma Primario Angulo FechadoGlaucoma PseudoexfoliativoUS 1 site in the US

Tied Tube Trial in Glaucoma Surgery

Washington University School of Medicine

📍 St Louis👥 152 participants📅 Completion: 2025-01

View details →Refer patient →ClinicalTrials.gov ↗

N/DGlaucomaUS 1 site in the US

Ocular Blood Flow Imaging for Glaucoma Assessment

University of Maryland, Baltimore

📍 Baltimore👥 150 participants📅 Completion: 2027-04

View details →Refer patient →ClinicalTrials.gov ↗

Fase 1Neovascular Age Related Macular DegenerationUS 28 sites in the US

Study of AR-14034 in Participants With Neovascular Age-Related Macular Degeneration (nAMD)

Alcon Research

📍 Abilene, Austin, Burlington, Colorado Springs, Coon Rapids, Dallas, Dothan, Erie👥 140 participants📅 Completion: 2027-10

View details →Refer patient →ClinicalTrials.gov ↗

N/DBest Vitelliform Macular DystrophyRetinitis PigmentosaUS 1 site in the US

Study of BEST1 Vitelliform Macular Dystrophy

Columbia University

📍 New York👥 52 participants📅 Completion: 2026-05

View details →Refer patient →ClinicalTrials.gov ↗

N/DPrimary Open Angle GlaucomaHipertensao OcularUS 1 site in the US

Nanodropper Use in Primary Open-Angle Glaucoma Patients: A Non-Inferiority Trial

59th Medical Wing

📍 Lackland Air Force Base👥 30 participants📅 Completion: 2024-03

View details →Refer patient →ClinicalTrials.gov ↗

Fase 1Neovascular Age Related Macular DegenerationUS 3 sites in the US

Safety and Tolerability of OCU-10-C-110 for Injection in Subjects With Neovascular Age-related Macular Degeneration

Ocugenix Corporation

📍 Abilene, Carmel, Willow Park👥 19 participants📅 Completion: 2026-11

View details →Refer patient →ClinicalTrials.gov ↗

N/DAge Related Macular DegenerationUS 1 site in the US

Progression of Early Atrophic Lesions

University of Utah

📍 Salt Lake City👥 125 participants📅 Completion: 2028-12

View details →Refer patient →ClinicalTrials.gov ↗

Fase 1Neovascular Age Related Macular DegenerationUS 3 sites in the US

Phase I/II Study of SKG0106 Intravitreal Injection in Patients With Neovascular Age-related Macular Degeneration (nAMD)

Skyline Therapeutics (US) Inc.

📍 Boston, Katy, Norfolk👥 68 participants📅 Completion: 2026-01

View details →Refer patient →ClinicalTrials.gov ↗

N/DGlaucoma Primario Angulo AbertoUS 1 site in the US

Glaukos® iStent Infinite Trabecular Micro-Bypass System in Subjects With Mild to Moderate Primary Open-angle Glaucoma

Glaukos Corporation

📍 Cincinnati👥 245 participants📅 Completion: 2027-08

View details →Refer patient →ClinicalTrials.gov ↗

Fase 1Atrofia GeograficaUS 7 sites in the US

Study of VOY-101 in Patients With Advanced Non-Neovascular Age-Related Macular Degeneration

Perceive Biotherapeutics, Inc.

📍 Burleson, Encino, Sacramento, Salt Lake City, San Diego, Scottsdale, Southlake👥 60 participants📅 Completion: 2028-03

View details →Refer patient →ClinicalTrials.gov ↗

N/DGlaucomaUS 1 site in the US

Community Based Treatment for (ComBaT) Glaucoma

University of Michigan

📍 Detroit👥 60 participants📅 Completion: 2027-05

View details →Refer patient →ClinicalTrials.gov ↗

N/DOptic NeuropathyGlaucomaUS 1 site in the US

Hyperbaric Oxygen Therapy for Optic Neuropathies

Stanford University

📍 Palo Alto👥 60 participants📅 Completion: 2027-12

View details →Refer patient →ClinicalTrials.gov ↗

Fase 2Glaucoma Angulo Aberto PrimarioUS 3 sites in the US

A Study of AMDX-2011P in Participants With Primary Open Angle Glaucoma

Amydis Inc.

📍 Glendale, Newport Beach, Phoenix👥 50 participants📅 Completion: 2025-02

View details →Refer patient →ClinicalTrials.gov ↗

N/DRetinopatia DiabeticaUS 1 site in the US

Video-based Patient Education Intervention for Diabetic Eye Screening in Latinx Communities

University of Wisconsin, Madison

📍 Madison👥 1526 participants📅 Completion: 2026-05

View details →Refer patient →ClinicalTrials.gov ↗

N/DPrimary Open Angle GlaucomaUS 1 site in the US

Safety and Effectiveness of Minimally Invasive Micro Sclerostomy (MIMS®) to Reduce Intraocular Pressure in Open-Angle Glaucoma Which is Not Controlled Despite Polypharmacy

Sanoculis Ltd

📍 Dallas👥 129 participants📅 Completion: 2025-12

View details →Refer patient →ClinicalTrials.gov ↗

N/DRetinitis PigmentosaCoroideremiaDistrofia Macular de StargardtUS 1 site in the US

Observational Study to Assess Endpoint Operational Feasibility & Measurement Properties in Patients with Retinal Degeneration

Ray Therapeutics, Inc.

📍 Irvine👥 120 participants📅 Completion: 2026-04

View details →Refer patient →ClinicalTrials.gov ↗

N/DStargardt Disease Type 1US 14 sites in the US

An Observational Study in Subjects to Follow the Progression of Stargardt Disease Type 1 (STGD1) Caused by Bi-Allelic Autosomal Recessive Mutations in the ABCA4 Gene

Splice Bio

📍 Ann Arbor, Atlanta, Aurora, Baltimore, Boston, Dallas, Durham, Gainesville👥 75 participants📅 Completion: 2027-02

View details →Refer patient →ClinicalTrials.gov ↗

N/DStargardt DiseaseCone Rod DystrophyUS 8 sites in the US

Prescreening Study to Identify Potential Stargardt Participants for ACDN-01 Clinical Trials (STARPATH)

Ascidian Therapeutics, Inc

📍 Ann Arbor, Baltimore, Boston, Cincinnati, Dallas, Gainesville, Houston, San Francisco👥 50 participants📅 Completion: 2030-08

View details →Refer patient →ClinicalTrials.gov ↗

Fase 1Stargardt DiseaseCone Rod DystrophyUS 10 sites in the US

Study to Evaluate ACDN-01 in ABCA4-related Stargardt Retinopathy (STELLAR)

Ascidian Therapeutics, Inc

📍 Ann Arbor, Baltimore, Boston, Cincinnati, Dallas, Gainesville, Houston, Miami👥 15 participants📅 Completion: 2030-12

View details →Refer patient →ClinicalTrials.gov ↗

Fase 3Geographic AtrophyUS 150 sites in the US

A Study Investigating Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Adult Participants With Geographic Atrophy

Regeneron Pharmaceuticals

📍 Abilene, Albuquerque, Asheville, Augusta, Aurora, Austin, Baltimore, Bellaire👥 975 participants📅 Completion: 2032-05

View details →Refer patient →ClinicalTrials.gov ↗

N/DGlaucomaControle SaudavelUS 1 site in the US

Perimetric Testing With Virtual Reality

Envision Health Technologies, Inc.

📍 Chicago👥 60 participants📅 Completion: 2024-10

View details →Refer patient →ClinicalTrials.gov ↗

Fase 2Dry Age Related Macular DegenerationUS 5 sites in the US

A Phase IIb Randomized, Multicenter Trial of Subretinal CPCB-RPE1 in Advanced Dry AMD (Geographic Atrophy)

Regenerative Patch Technologies, LLC

📍 Beverly Hills, Huntington Beach, Lemont, Los Angeles, The Woodlands👥 24 participants📅 Completion: 2040-12

View details →Refer patient →ClinicalTrials.gov ↗

N/DGlaucomaUS 1 site in the US

Tolerability of an Anesthesia-free Tonometer Tip

Duke University

📍 Durham👥 50 participants📅 Completion: 2026-03

View details →Refer patient →ClinicalTrials.gov ↗

Fase 1Degeneracao Macular Relacionada a IdadeRetinopatia DiabeticaGlaucomaUS 1 site in the US

The Role of Occupational Therapy for Improving Medication Management for Persons With AMD, DR and Glaucoma

MCPHS University

📍 Worcester👥 50 participants📅 Completion: 2026-12

View details →Refer patient →ClinicalTrials.gov ↗

N/DPrimary Open Angle GlaucomaUS 2 sites in the US

A Real-World Evidence Study of Goniotomy With the C-REX™ Instrument in Patients With Primary Open Angle Glaucoma

Iantrek, Inc.

📍 Atlanta, Crossville👥 200 participants📅 Completion: 2026-10

View details →Refer patient →ClinicalTrials.gov ↗

N/DGlaucomaOcular HypertensionUS 1 site in the US

Implementing AI-based Glaucoma Screening Within Federally Qualified Health Centers

University of Alabama at Birmingham

📍 Birmingham👥 1800 participants📅 Completion: 2029-09

View details →Refer patient →ClinicalTrials.gov ↗

Fase 2Atrofia GeograficaUS 45 sites in the US

A Long-term Extension Study of JNJ-81201887 (AAVCAGsCD59) Parent Studies in Participants With Geographic Atrophy (GA) Secondary to Age-related Macular Degeneration (AMD)

Janssen Research & Development, LLC

📍 Asheville, Austin, Baltimore, Beaufort, Boston, Carmel, Chevy Chase, Cincinnati👥 274 participants📅 Completion: 2030-07

View details →Refer patient →ClinicalTrials.gov ↗

Fase 2Geographic AtrophyAge Related Macular DegenerationUS 27 sites in the US

Study to Evaluate Efficacy and Safety of ONL1204 in Patients With GA Associated With AMD

ONL Therapeutics

📍 Beaumont, Bellaire, Bellevue, Carmel, Colorado Springs, Elmhurst, Erie, Gilbert👥 324 participants📅 Completion: 2028-11

View details →Refer patient →ClinicalTrials.gov ↗

Fase 2Atrofia Geografica Nao Foveal DmriUS 3 sites in the US

A Phase 2 Efficacy and Safety Study of GAL-101, 2% Ophthalmic Solution in Non-foveal Geographic Atrophy Secondary to Non-neovascular AMD

Galimedix Therapeutics Inc

📍 Beverly Hills, Hagerstown, Walnut Creek👥 110 participants📅 Completion: 2027-05

View details →Refer patient →ClinicalTrials.gov ↗

Fase 4Edema Macular DiabeticoUS 1 site in the US

High Dose Aflibercept in Diabetic Macular Edema in Patients With Previous Vitrectomy

Retina Consultants of Orange County

📍 Fullerton👥 15 participants📅 Completion: 2027-08

View details →Refer patient →ClinicalTrials.gov ↗

N/DGeographic AtrophyMacular DegenerationUS 59 sites in the US

A Study to Learn How Avacincaptad Pegol (Izervay™) is Used in Clinical Practice in People Who Have Geographic Atrophy

Astellas Pharma Global Development, Inc.

📍 Abilene, Augusta, Aurora, Bonita Springs, Brentwood, Colorado Springs, Columbus, Coral Gables👥 1000 participants📅 Completion: 2030-01

View details →Refer patient →ClinicalTrials.gov ↗

Fase 3Retinopatia Diabetica ProliferativaUS 20 sites in the US

Faricimab + PRP vs. Vitrectomy + Endolaser for Treatment of PDR

Jaeb Center for Health Research

📍 Augusta, Baltimore, Bellaire, Boston, Carmel, Huntington Beach, Lakeland, Lexington👥 426 participants📅 Completion: 2031-08

View details →Refer patient →ClinicalTrials.gov ↗

N/DAtrofia GeograficaDoenca de StargardtVisao Normal ControleUS 1 site in the US

A Prospective Observational Study to Assess the Reliability and Validity of the MLSDT

Nanoscope Therapeutics Inc.

📍 Dallas👥 30 participants📅 Completion: 2025-05

View details →Refer patient →ClinicalTrials.gov ↗

Fase 4Glaucoma Angulo AbertoHipertensao OcularUS 1 site in the US

Safety and Efficacy of iDose® TR With Cataract Surgery vs. Cataract Surgery Alone

Glaukos Corporation

📍 Kenosha👥 132 participants📅 Completion: 2027-06

View details →Refer patient →ClinicalTrials.gov ↗

N/DGlaucomaUS 1 site in the US

Glaucoma Screening to Enhance At-Risk Californians' Health

University of California, San Francisco

📍 Oakland👥 2000 participants📅 Completion: 2029-09

View details →Refer patient →ClinicalTrials.gov ↗

Fase 4Glaucoma Primario Angulo AbertoHipertensao OcularUS 1 site in the US

Effect of Rhopressa on Intraocular Pressure (IOP) in Patients With Primary Open-Angle Glaucoma or Ocular Hypertension Post-SLT

East Coast Institute for Research

📍 Jacksonville👥 70 participants📅 Completion: 2026-04

View details →Refer patient →ClinicalTrials.gov ↗

Fase 4Open Angle GlaucomaUS 1 site in the US

Efficacy of Simbrinza and Rocklatan vs Cosopt and Latanoprost

Prairie Eye Center

📍 Springfield👥 70 participants📅 Completion: 2026-04

View details →Refer patient →ClinicalTrials.gov ↗

N/DGlaucomaDoencas OcularesDeficiencia VisualUS 1 site in the US

Michigan Screening and Intervention for Glaucoma and Eye Health Through Telemedicine (SIGHT) 2

University of Michigan

📍 Flint👥 900 participants📅 Completion: 2030-08

View details →Refer patient →ClinicalTrials.gov ↗

Fase 1Stargardt DiseaseUS 5 sites in the US

A Phase 1/2, First-in-Human Dose Escalation/Expansion Study to Evaluate the Safety, Tolerability and Preliminary Efficacy of a Subretinal Injection of SB-007 in Subjects With Stargardt Disease (STGD1)

Splice Bio

📍 Aurora, Boston, Dallas, Miami, Portland👥 57 participants📅 Completion: 2028-12

View details →Refer patient →ClinicalTrials.gov ↗

Fase 1Atrofia GeograficaUS 16 sites in the US

A Study to Investigate Safety, Tolerability, Pharmacokinetics (PK), Pharmacodynamics (PD), and Immunogenicity of RO7669330 in Participants With Geographic Atrophy (GA) Secondary to Age-related Macular Degeneration (AMD)

Hoffmann-La Roche

📍 Augusta, Austin, Beverly Hills, Dallas, Erie, Germantown, Glendale, Hagerstown👥 132 participants📅 Completion: 2027-01

View details →Refer patient →ClinicalTrials.gov ↗

Fase 2Edema Macular DiabeticoUS 18 sites in the US

A Study to Test Whether BI 1815368 Helps People With an Eye Condition Called Diabetic Macular Edema

Boehringer Ingelheim

📍 Arcadia, Austin, Carmel, Dallas, Eugene, Hagerstown, Huntington Beach, Lakewood👥 300 participants📅 Completion: 2027-09

View details →Refer patient →ClinicalTrials.gov ↗

N/DGlaucomaUS 1 site in the US

Glaucoma Laser Assessment of Stability and Sustainability

Twin Cities Eye Consultants

📍 Coon Rapids👥 48 participants📅 Completion: 2027-08

View details →Refer patient →ClinicalTrials.gov ↗

Fase 2Glaucoma Angulo AbertoHipertensao OcularUS 1 site in the US

Evaluate Efficacy and Safety of PA5108 Ocular Implants in Primary Open Angle Glaucoma or Ocular Hypertension

PolyActiva Pty Ltd

📍 Newport Beach👥 75 participants📅 Completion: 2026-11

View details →Refer patient →ClinicalTrials.gov ↗

N/DMacular Degenerative DiseaseUS 1 site in the US

Effect of Lutein, Zeaxanthin, and Meso-Zeaxanthin Supplementation on Skin Carotenoid Concentration: A Six-Month, Placebo-Controlled Crossover Study

Insight Eyecare Specialties, Inc. dba Vision Source Eyecare,

📍 Kansas City👥 60 participants📅 Completion: 2026-12

View details →Refer patient →ClinicalTrials.gov ↗

N/DGlaucomaUS 1 site in the US

The Role of Music in Enhancing Attention During Visual Field Exams for Pediatric Glaucoma Patients

Johns Hopkins University

📍 Bethesda👥 40 participants📅 Completion: 2026-04

View details →Refer patient →ClinicalTrials.gov ↗

Fase 2Atrofia Geografica Degeneracao MacularUS 8 sites in the US

Phase 2 Study of ADX-038 in Participants With Geographic Atrophy

ADARx Pharmaceuticals, Inc.

📍 Beverly Hills, Erie, Gilbert, Hagerstown, McAllen, Phoenix, Round Rock, San Antonio👥 240 participants📅 Completion: 2027-12

View details →Refer patient →ClinicalTrials.gov ↗

Fase 1Intermediate Age Related Macular DegenerationUS 1 site in the US

Eggs and Age-related Macular Degeneration (EggsAMD) Study.

Kathryn Starr

📍 Durham👥 20 participants📅 Completion: 2026-09

View details →Refer patient →ClinicalTrials.gov ↗

N/DGlaucoma Primario Angulo AbertoHipertensao OcularSindrome de Dispersao de PigmentoUS 1 site in the US

A Prospective Study on the Efficacy of Direct Selective Laser Trabeculoplasty (DSLT) in Achieving >20% Intraocular Pressure (IOP) Reduction Without Medications at 6 Months in Naive, Untreated Glaucoma Patients

Brian Shafer

📍 Plymouth Meeting👥 60 participants📅 Completion: 2026-06

View details →Refer patient →ClinicalTrials.gov ↗

N/DGeographic Atrophy Secondary to AmdUS 6 sites in the US

A Non-Interventional Study Observing Short-Term Progression in Geographic Atrophy (GA)

Complement Therapeutics

📍 Bethlehem, Carmel, Dallas, La Crosse, Mountain View, Reno👥 75 participants📅 Completion: 2027-06

View details →Refer patient →ClinicalTrials.gov ↗

N/DPrimary Open Angle GlaucomaUS 1 site in the US

Direct Selective Laser Trabeculoplasty (DSLT) for Reducing Eye Pressure in Non-Caucasian Patients With Open Angle Glaucoma

Select Eye Care

📍 Elkridge👥 60 participants📅 Completion: 2026-10

View details →Refer patient →ClinicalTrials.gov ↗

N/DRetinal DiseaseGlaucomaCorneal DiseasesUS 3 sites in the US

Data Gathering for A10900

Optos, PLC

📍 Anaheim, Germantown, West Hartford👥 180 participants📅 Completion: 2026-05

View details →Refer patient →ClinicalTrials.gov ↗

N/DDiabetesRetinopatia DiabeticaUS 1 site in the US

Pivotal Trial of Automated Artificial Intelligence (AI) Based System for Early Diagnosis of Diabetic Retinopathy

iHealthScreen Inc

📍 Richmond Hill👥 922 participants📅 Completion: 2027-07

View details →Refer patient →ClinicalTrials.gov ↗

Fase 1Atrofia Geografica Secundaria a Dmri SecaUS 1 site in the US

A Phase 1/2 Study to Evaluate the Safety and Efficacy of Intravitreal Administration of BS01 in Patients With Geographic Atrophy Secondary to Dry AMD

Bionic Sight LLC

📍 Edison👥 40 participants📅 Completion: 2031-12

View details →Refer patient →ClinicalTrials.gov ↗

Fase 1Atrofia Geografica Degeneracao MacularUS 4 sites in the US

Study to Assess the Adverse Events and How Intravitreal ABBV-6628 Moves Through the Body of Adult Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration

AbbVie

📍 Abilene, Carmel, Dallas, The Woodlands👥 66 participants📅 Completion: 2029-10

View details →Refer patient →ClinicalTrials.gov ↗

Fase 1Stargardt DiseaseUS 4 sites in the US

A Study of AAVB-039 in Participants With Stargardt Disease (STGD1)

AAVantgarde Bio Srl

📍 Bellaire, Dallas, Los Angeles, Rochester👥 75 participants📅 Completion: 2032-07

View details →Refer patient →ClinicalTrials.gov ↗

Fase 2Atrofia GeograficaUS 1 site in the US

SGLT2 Inhibitors in Geographic Atrophy

Washington University School of Medicine

📍 St Louis👥 70 participants📅 Completion: 2028-06

View details →Refer patient →ClinicalTrials.gov ↗

Fase 1Best Vitelliform Macular DystrophyAutosomal Recessive BestrophinopathyUS 3 sites in the US

Safety and Tolerability of Subretinally Injected OPGx-BEST1 in Patients With Best Vitelliform Macular Dystrophy (BVMD) or Autosomal-Recessive Bestrophinopathy (ARB)

Opus Genetics, Inc

📍 Cincinnati, Dallas, Los Angeles👥 10 participants📅 Completion: 2030-08

View details →Refer patient →ClinicalTrials.gov ↗

Fase 2Degeneracao Macular NeovascularOclusao de Veia de Ramo RetinianaUS 49 sites in the US

A Dose-masked Study of Intravitreal EYE103 in Participants With NVAMD or Macular Edema Following BRVO

EyeBiotech Ltd.

📍 Abilene, Amarillo, Asheville, Austin, Bellaire, Bloomfield, Burleson, Cary👥 160 participants📅 Completion: 2028-06

View details →Refer patient →ClinicalTrials.gov ↗

Fase 1Atrofia Geografica DmriUS 13 sites in the US

A Safety and Efficacy Study of a One-time Intravitreal Injection of SAR446597 in Participants With Geographic Atrophy Secondary to Age-related Macular Degeneration

Sanofi

📍 Austin, Bethlehem, Chevy Chase, Dallas, Eugene, Gainesville, Hagerstown, Lemont👥 104 participants📅 Completion: 2032-07

View details →Refer patient →ClinicalTrials.gov ↗

Fase 2Atrofia Geografica Secundaria a Degeneracao Macular Relacionada a IdadeUS 43 sites in the US

A Phase 2, Randomized, Placebo Controlled, Multicenter, Masked Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacodynamics of Multidose APL 3007 in Combination With Syfovre/Pegcetacoplan (APL-2) in Patients Diagnosed With Geographic Atrophy Secondary to Age Related Macular Degeneratio

Apellis Pharmaceuticals, Inc.

📍 Abilene, Augusta, Austin, Bakersfield, Bellaire, Cleveland, Dallas, Encino👥 240 participants📅 Completion: 2027-11

View details →Refer patient →ClinicalTrials.gov ↗

Fase 4Glaucoma Angulo AbertoHipertensao OcularSuspeito de GlaucomaUS 1 site in the US

Biomarkers of Ocular Surface Damage in the Setting of Topical Ocular Hypotensive Medication Use

University of Miami

📍 Miami👥 20 participants📅 Completion: 2028-01

View details →Refer patient →ClinicalTrials.gov ↗

Fase 3CataractGlaucomaOcular HypertensionUS 1 site in the US

Evaluation of the Safety and Efficacy of the Bimatoprost Implant System Used in Combination With the SpyGlass IOL Compared to Timolol Ophthalmic Solution (Rhine)

SpyGlass Pharma, Inc.

📍 Houston👥 400 participants📅 Completion: 2031-03

View details →Refer patient →ClinicalTrials.gov ↗

N/DOpen Angle GlaucomaUS 5 sites in the US

Safety and Effectiveness of the VisiPlate Aqueous Shunt in Patients With Refractory Open-Angle Glaucoma

Avisi Technologies Inc.

📍 Dallas, Glendale, Grand Junction, Kenosha, Sacramento👥 165 participants📅 Completion: 2027-10

View details →Refer patient →ClinicalTrials.gov ↗

N/DDiabetic RetinopathyUS 2 sites in the US

Assessment of AI Program 'DRISTi' as a Screening Tool

Artelus AI

📍 Oxford, Raleigh👥 900 participants📅 Completion: 2026-03

View details →Refer patient →ClinicalTrials.gov ↗

Fase 1Geographic AtrophyUS 4 sites in the US

Intravitreal (IVT) Pozelimab for Geographic Atrophy (GA) in Adult Participants

Regeneron Pharmaceuticals

📍 Austin, East Weymouth, Lakewood, The Woodlands👥 54 participants📅 Completion: 2028-07

View details →Refer patient →ClinicalTrials.gov ↗

Fase 3Retinopatia Diabetica Nao ProliferativaUS 1 site in the US

A Study to Evaluate the Efficacy and Safety of OTX-TKI (Axitinib Implant) in Participants With Non-Proliferative Diabetic Retinopathy

Ocular Therapeutix, Inc.

📍 Hagerstown👥 930 participants📅 Completion: 2027-03

View details →Refer patient →ClinicalTrials.gov ↗

N/DPigmentary Dispersion SyndromeGlaucoma PigmentarUS 1 site in the US

IOP Reduction in Pigmentary Glaucoma Using DSLT

Mann Eye Institute

📍 Houston👥 45 participants📅 Completion: 2027-04

View details →Refer patient →ClinicalTrials.gov ↗

Fase 1Glaucoma Angulo AbertoNeuropatia Optica Isquemica Anterior Nao ArteríticaUS 2 sites in the US

Evaluating ER-100 for Safety in People With Glaucoma or Non-Arteritic Anterior Ischemic Optic Neuropathy (Optic Nerve Conditions)

Life Biosciences Inc.

📍 Charleston, Glendale👥 18 participants📅 Completion: 2032-03

View details →Refer patient →ClinicalTrials.gov ↗

N/DDiabetic RetinopathyUS 1 site in the US

Using Implementation Science to Adapt a Targeted Transportation Intervention for Patients With Diabetic Retinopathy (PRONTO-EYE)

University of Illinois at Chicago

📍 Chicago👥 60 participants📅 Completion: 2027-06

View details →Refer patient →ClinicalTrials.gov ↗

N/DDegeneracao Macular Relacionada Idade SecaRetina Saudavel ControleUS 1 site in the US

Ocular Proteomics Testing In Chronic Atrophy

ClinOmicsAI

📍 Erie👥 50 participants📅 Completion: 2026-07

View details →Refer patient →ClinicalTrials.gov ↗

N/DGlaucomaGlaucoma SuspeitoUS 1 site in the US

Automated Applanation Tonometry - Updated

Duke University

📍 Durham👥 200 participants📅 Completion: 2026-12

View details →Refer patient →ClinicalTrials.gov ↗

Fase 2Glaucoma de Angulo AbertoGlaucoma de Tensao NormalRetinopatia Diabetica Nao ProliferativaUS 1 site in the US

Single-site Pilot Study Evaluating the Effect of QLS-111 Ophthalmic Solution on Posterior Perfusion and Vessel Dilation

Qlaris Bio, Inc.

📍 Palo Alto👥 14 participants📅 Completion: 2026-06

View details →Refer patient →ClinicalTrials.gov ↗

Fase 2Glaucoma Angulo AbertoHipertensao OcularUS 1 site in the US

Study of QLS-111-FDC in Open-Angle Glaucoma or Ocular Hypertension

Qlaris Bio, Inc.

📍 Largo👥 60 participants📅 Completion: 2026-07

View details →Refer patient →ClinicalTrials.gov ↗

N/DNormal Healthy EyesGlaucomaRetinal DiseaseUS 1 site in the US

Performance Evaluation of Dream OCT: AP Study

Intalight, Inc

📍 Chicago👥 120 participants📅 Completion: 2026-04

View details →Refer patient →ClinicalTrials.gov ↗

Fase 1Atrofia Geografica Secundaria a Degeneracao Macular Relacionada a IdadeUS 3 sites in the US

An Optimised GA Interventional Trial (Opti-GAIN) to Test if Treatment With CTx001 is Safe and Works for People With Geographic Atrophy (GA)

Complement Therapeutics

📍 Carmel, Dallas, Reno👥 75 participants📅 Completion: 2032-06

View details →Refer patient →ClinicalTrials.gov ↗

Fase 3Stargardt DiseaseUS 1 site in the US

Study of ALK-001 on the Progression of Stargardt Disease

Alkeus Pharmaceuticals, Inc.

📍 Erie👥 230 participants📅 Completion: 2030-12

View details →Refer patient →ClinicalTrials.gov ↗

N/DCataractGlaucomaUS 1 site in the US

To Study Ocular Outflow Dynamics of the Eye Using Intraoperative Tonographic Biometry and Assess Its Predictive Value in Improving Postoperative Outcomes.

The New York Eye & Ear Infirmary

📍 New York👥 150 participants📅 Completion: 2028-12

View details →Refer patient →ClinicalTrials.gov ↗

N/DStargardt DiseaseStargardt Like Macular DystrophyUS 3 sites in the US

A Study to Learn How Stargardt-type Eye Conditions Progress in Children and Adults

Astellas Pharma Global Development, Inc.

📍 Dallas, Durham, Palo Alto👥 90 participants📅 Completion: 2028-07

View details →Refer patient →ClinicalTrials.gov ↗

N/DGlaucoma Angulo AbertoHipertensao OcularUS 1 site in the US

Change in IOP Fluctuation After DSLT

Ophthalmology Associates, Fort Worth

📍 Fort Worth👥 40 participants📅 Completion: 2027-04

View details →Refer patient →ClinicalTrials.gov ↗

Fase 1Stargardt DiseaseUS 3 sites in the US

Phase 1/2 Open-Label Dose-Escalation Study to Evaluate Safety of a Single Intravitreal Injection of RTx-021 in Patients With Stargardt Disease

Ray Therapeutics, Inc.

📍 Bakersfield, Bellaire, Pittsburgh👥 18 participants📅 Completion: 2030-12

View details →Refer patient →ClinicalTrials.gov ↗

Fase 2Atrofia Geografica Secundaria a DmriUS 5 sites in the US

A Study to Investigate Efficacy and Safety of FWY003 Compared With Placebo in Participants With Geographic Atrophy Secondary to Age-related Macular Degeneration

Novartis Pharmaceuticals

📍 Boston, Boynton Beach, Deerfield Beach, Huntington Beach, St. Petersburg👥 272 participants📅 Completion: 2029-08

View details →Refer patient →ClinicalTrials.gov ↗

N/DDegeneracao Macular Relacionada a Idade SecaControles Saudaveis Sem DmriUS 1 site in the US

Real-World Evaluation of AI Enabled Multi-Spectral Imaging (MSI) for AMD Biomarker Detection

AI-Spectral

📍 Woodbridge👥 1000 participants📅 Completion: 2026-09

View details →Refer patient →ClinicalTrials.gov ↗

N/DRetinitis PigmentosaDistrofia Macular de StargardtAtrofia Geografica Por DmriUS 1 site in the US

Development and Evaluation of Functional Visual Field and Navigation Endpoints in Moderate to Profound Inherited Retinal Disease (DEFINE-IRD)

Ray Therapeutics, Inc.

📍 Irvine👥 25 participants📅 Completion: 2027-02

View details →Refer patient →ClinicalTrials.gov ↗

N/DGlaucomaUS 1 site in the US

Glaucoma Related Quality of Life

Marc Toeteberg-Harms

📍 Iowa City👥 5000 participants📅 Completion: 2027-05

View details →Refer patient →ClinicalTrials.gov ↗

N/DDiabetic RetinopathyMacular EdemaUS 1 site in the US

Video Intervention to Improve Understanding of Diabetic Retinopathy at Zuckerberg San Francisco General Hospital and Trauma Center

University of California, San Francisco

📍 San Francisco👥 150 participants📅 Completion: 2027-12

View details →Refer patient →ClinicalTrials.gov ↗

Questions or requests?

Data deletion (LGPD/GDPR), partnerships, referrals, or any other matter.

Ophthalmology clinical trialsrecruiting in the United States and Brazil

Diagnostic Innovations in Glaucoma Study

National Eye Institute Biorepository for Retinal Diseases

High Resolution Retinal Imaging

Eye Pressure Lowering Surgery

Functional and Structural Imaging for Glaucoma

OCT Angiography in Wet AMD

Inherited Retinal Degenerative Disease Registry

Rod and Cone Mediated Function in Retinal Disease

Clinical Applications of Advanced Ophthalmic Imaging

A Study of the Safety and Tolerability of ASP7317 in Senior Adults Who Are Losing Their Clear, Sharp Central Vision Due to Geographic Atrophy Secondary to Dry Age-related Macular Degeneration

Liver X Receptor (LXR) as a Novel Therapeutic Target in Diabetic Retinopathy (DR)

Human iPSC for Repair of Vasodegenerative Vessels in Diabetic Retinopathy

Caffeine Consumption in Glaucoma Patients and Healthy Subjects

Intraoperative OCT Guidance of Intraocular Surgery II

Village-Integrated Eye Worker Trial II

Pilocarpine Use After Kahook Goniotomy

Feasibility and Safety of MB-102 in Ocular Angiography as Compared to Fluorescein Sodium

Therapeutic Contact Lens Drug Delivery System (TCL-DDS) in Patients With Recurrent Cystoid Macular Edema

Autologous Transplantation of Induced Pluripotent Stem Cell-Derived Retinal Pigment Epithelium for Geographic Atrophy Associated With Age-Related Macular Degeneration

Treatment of Ocular Discomfort in Glaucoma Patients Using Multiple Topical Medications

AGN-193408 SR in the Treatment of Open-angle Glaucoma or Ocular Hypertension

MMP-9 Inhibition for Recalcitrant Wet AMD

Optical Coherence Tomography Angiography in Subjects With Retinal Vascular Disease

Sleep, Diabetic Retinopathy and Melatonin

Safety and Tolerability of RPE Stem Cell-derived RPE(RPESC-RPE) Transplantation in Patients With Dry Age-related Macular Degeneration (AMD)

Fenofibrate for Prevention of DR Worsening

Clarifying the Optimal Application of SLT Therapy Trial

Biomarker of Diabetic Retinopathy

4D-150 in Patients With Neovascular (Wet) Age-Related Macular Degeneration

Topical Insulin for Glaucoma

Retinal Blood Flow and Autoregulation

Adaptive Optics Retinal Imaging

Multicenter Clinical Study of the SING-IMT in Patients with Late-stage AMD

Factors in Learning And Plasticity: Macular Degeneration

ACCESS 2: AI for pediatriC diabetiC Eye examS Study 2

Comparison of Intraocular Pressure Measurement With the Novel TonoVera Device With Other Commonly Used Devices

Imaging Retinal Vasculature in Infant Eyes

Cataract Surgery in Conjunction With Ab-interno Canaloplasty Compared to Cataract Surgery Only in Patients With Mild to Moderate Primary Open-Angle Glaucoma

Results of Patients With Glaucoma Undergoing Minimally Invasive Glaucoma Surgery in Conjunction With Cataract Surgery

A Study to Optimize Subretinal Surgical Delivery and to Evaluate Safety and Activity of Opregen in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration (GAlette); Adaptive Optics (AO) Retinal Imaging Substudy in Association With Study GR44251

Tissue Repository Providing Annotated Biospecimens for Approved Investigator-directed Biomedical Research Initiatives

Tied Tube Trial in Glaucoma Surgery

Ocular Blood Flow Imaging for Glaucoma Assessment

Study of AR-14034 in Participants With Neovascular Age-Related Macular Degeneration (nAMD)

Study of BEST1 Vitelliform Macular Dystrophy

Nanodropper Use in Primary Open-Angle Glaucoma Patients: A Non-Inferiority Trial

Safety and Tolerability of OCU-10-C-110 for Injection in Subjects With Neovascular Age-related Macular Degeneration

Progression of Early Atrophic Lesions

Phase I/II Study of SKG0106 Intravitreal Injection in Patients With Neovascular Age-related Macular Degeneration (nAMD)

Glaukos® iStent Infinite Trabecular Micro-Bypass System in Subjects With Mild to Moderate Primary Open-angle Glaucoma

Study of VOY-101 in Patients With Advanced Non-Neovascular Age-Related Macular Degeneration

Community Based Treatment for (ComBaT) Glaucoma

Hyperbaric Oxygen Therapy for Optic Neuropathies

A Study of AMDX-2011P in Participants With Primary Open Angle Glaucoma

Video-based Patient Education Intervention for Diabetic Eye Screening in Latinx Communities

Safety and Effectiveness of Minimally Invasive Micro Sclerostomy (MIMS®) to Reduce Intraocular Pressure in Open-Angle Glaucoma Which is Not Controlled Despite Polypharmacy

Observational Study to Assess Endpoint Operational Feasibility & Measurement Properties in Patients with Retinal Degeneration

An Observational Study in Subjects to Follow the Progression of Stargardt Disease Type 1 (STGD1) Caused by Bi-Allelic Autosomal Recessive Mutations in the ABCA4 Gene

Prescreening Study to Identify Potential Stargardt Participants for ACDN-01 Clinical Trials (STARPATH)

Study to Evaluate ACDN-01 in ABCA4-related Stargardt Retinopathy (STELLAR)

A Study Investigating Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Adult Participants With Geographic Atrophy

Perimetric Testing With Virtual Reality

A Phase IIb Randomized, Multicenter Trial of Subretinal CPCB-RPE1 in Advanced Dry AMD (Geographic Atrophy)

Tolerability of an Anesthesia-free Tonometer Tip

The Role of Occupational Therapy for Improving Medication Management for Persons With AMD, DR and Glaucoma

A Real-World Evidence Study of Goniotomy With the C-REX™ Instrument in Patients With Primary Open Angle Glaucoma

Implementing AI-based Glaucoma Screening Within Federally Qualified Health Centers

A Long-term Extension Study of JNJ-81201887 (AAVCAGsCD59) Parent Studies in Participants With Geographic Atrophy (GA) Secondary to Age-related Macular Degeneration (AMD)

Study to Evaluate Efficacy and Safety of ONL1204 in Patients With GA Associated With AMD

A Phase 2 Efficacy and Safety Study of GAL-101, 2% Ophthalmic Solution in Non-foveal Geographic Atrophy Secondary to Non-neovascular AMD

High Dose Aflibercept in Diabetic Macular Edema in Patients With Previous Vitrectomy

A Study to Learn How Avacincaptad Pegol (Izervay™) is Used in Clinical Practice in People Who Have Geographic Atrophy

Faricimab + PRP vs. Vitrectomy + Endolaser for Treatment of PDR

A Prospective Observational Study to Assess the Reliability and Validity of the MLSDT

Safety and Efficacy of iDose® TR With Cataract Surgery vs. Cataract Surgery Alone

Glaucoma Screening to Enhance At-Risk Californians' Health

Effect of Rhopressa on Intraocular Pressure (IOP) in Patients With Primary Open-Angle Glaucoma or Ocular Hypertension Post-SLT

Efficacy of Simbrinza and Rocklatan vs Cosopt and Latanoprost

Michigan Screening and Intervention for Glaucoma and Eye Health Through Telemedicine (SIGHT) 2

Ophthalmology clinical trials
recruiting in the United States and Brazil